Acute Kidney Injury in COVID-19

Głowacka, Marta; Lipka, Sara; Młynarska, Ewelina; Franczyk, Beata; Rysz, Jacek

doi:10.3390/ijms22158081

Cited by 54 publications

(74 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum creatinine derived from phosphocreatine during energy-producing processes in muscles, brain, and myocardium is effectively eliminated in kidneys from the blood circulation system. An abnormally elevated creatinine level in blood indicates poor clearance of creatinine, malfunction of kidneys, and possible progression of kidney disease due to insufficient detoxification of the organism in acute or chronic inflammation [ 48 , 49 , 50 , 51 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

Karosanidze¹,

Kiladze²,

Kirtadze³

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Currently, no effective treatment of comorbid complications or COVID-19 long-haulers during convalescence is known. This randomized, quadruple-blind, placebo-controlled trial aimed to assess the efficacy of adaptogens on the recovery of patients with Long COVID symptoms. One hundred patients with confirmed positive SARS-CoV-2 test, discharged from COVID Hotel isolation, Intensive Care Unit (ICU), or Online Clinics, and who experienced at least three of nine Long COVID symptoms (fatigue, headache, respiratory insufficiency, cognitive performance, mood disorders, loss of smell, taste, and hair, sweatiness, cough, pain in joints, muscles, and chest) in the 30 days before randomization were included in the study of the efficacy of Chisan®/ADAPT-232 (a fixed combination of adaptogens Rhodiola, Eleutherococcus, and Schisandra) supplementation for two weeks. Chisan® decreased the duration of fatigue and pain for one and two days, respectively, in 50% of patients. The number of patients with lack of fatigue and pain symptoms was significantly less in the Chisan® treatment group than in the placebo group on Days 9 (39% vs. 57%, pain relief, p = 0.0019) and 11 (28% vs. 43%, relief of fatigue, * p = 0.0157). Significant relief of severity of all Long COVID symptoms over the time of treatment and the follow-up period was observed in both groups of patients, notably decreasing the level of anxiety and depression from mild and moderate to normal, as well as increasing cognitive performance in patients in the d2 test for attention and increasing their physical activity and workout (daily walk time). However, the significant difference between placebo and Chisan® treatment was observed only with a workout (daily walk time) and relieving respiratory insufficiency (cough). A clinical assessment of blood markers of the inflammatory response (C-reactive protein) and blood coagulation (D-dimer) did not reveal any significant difference over time between treatment groups except significantly lower IL-6 in the Chisan® treatment group. Furthermore, a significant difference between the placebo and Chisan® treatment was observed for creatinine: Chisan® significantly decreased blood creatinine compared to the placebo, suggesting prevention of renal failure progression in Long COVID. In this study, we, for the first time, demonstrate that adaptogens can increase physical performance in Long COVID and reduce the duration of fatigue and chronic pain. It also suggests that Chisan®/ADAPT-232 might be useful for preventing the progression of renal failure associated with increasing creatinine.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

Karosanidze¹,

Kiladze²,

Kirtadze³

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…This could be associated with possible protein leakage and albuminuria. SARS-CoV-2 can directly infect the renal parenchyma and induce renal damage, which may be associated with a spectrum of renal manifestation ranging from mild protein leakage to collapsing glomerulopathy [ 43 – 45 ]. Our findings suggest that albuminuria is only a short-term complication of mild COVID-19, as our multivariable repeated measures showed minor fluctuations of serum albumin at 3- and 6-month post-infection that were statistically not significant.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and renal involvement: a prospective cohort study assessing the impact of mild SARS-CoV-2 infection on the kidney function of young healthy males

et al. 2022

View full text Add to dashboard Cite

Purpose COVID-19 frequently affects the kidneys with symptoms ranging from mild proteinuria to progressive acute kidney injury. This prospective study aimed to assess the short- and long-term impact of asymptomatic and mild COVID-19 on the renal function of healthy young adults, and to determine the correlation between viral load and kidney function among these patients. Methods This was a prospective cohort study conducted over a period of 6 months. Patients were followed-up at baseline, and then after 3 and 6 months, respectively. Real-time PCR cycle threshold (CT) was used to determine the viral load and disease activity. Patients were classified into two groups with either asymptomatic COVID-19 or mild pneumonia. The assessment parameters were variables that could directly or indirectly relate to the renal function. Results A total of 48 patients were included and evaluated. The majority of patients (62.5%) had asymptomatic COVID-19 disease. Patients with mild pneumonia had significantly higher serum creatinine (SCr) at the time of COVID-19 diagnosis (beta = 12.836, 95% CI = 2.405–23.268, P = 0.019), after 3 months (beta = 14.345, 95% CI = 1.149–27.542, P = 0.035), and after 6 months (beta = 14.100, 95% CI = 0.730–27.470, P = 0.040) compared to asymptomatic patients. Mild pneumonia was also significantly associated with lower serum albumin level at the time of COVID-19 diagnosis (beta = – 6.317, 95% CI = – 9.448–− 3.185, P < 0.001). Conclusion Mild COVID-19 is associated with mild renal involvement without AKI. Changes in the renal function appear to be related to reduced creatinine clearance and possible albumin leakage in the acute phase of the disease. The reduction in creatinine clearance is not predicted by viral load, and it appears to be a long-term effect of the disease that can last for at least 6 months.

show abstract

“…We are seeing emergent evidence that treatment for one variant does not necessarily work on another – look especially at the recent outbreak related to the delta variant in Israel where vaccination rates were very high. The Covid-19 virus has been documented to cause over 60 different symptoms across 10 different bodily systems, 2 affecting tissues such as pulmonary, renal, intestinal, vascular and neural, 3 , 4 , 5 producing a wide range of different short and long terms problems. It can also cause immune system dysregulation, trigger abnormal inflammatory processes.…”

Section: What Is Covid-19 and What Are The Sequelae Of Covid-19?mentioning

confidence: 99%

Reflections on the potential role of acupuncture and Chinese herbal medicine in the treatment of COVID-19 and subsequent health problems

Birch

Alræk

Gröbe³

2021

Integrative Medicine Research

View full text Add to dashboard Cite

Acute Kidney Injury in COVID-19

Cited by 54 publications

References 43 publications

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial

COVID-19 and renal involvement: a prospective cohort study assessing the impact of mild SARS-CoV-2 infection on the kidney function of young healthy males

Reflections on the potential role of acupuncture and Chinese herbal medicine in the treatment of COVID-19 and subsequent health problems

Contact Info

Product

Resources

About